A Look At Caris Life Sciences (CAI) Valuation As Shares Lose Momentum In Recent Months

Simply Wall St.04-25 21:05

AdvertisementWhy Caris Life Sciences Is On Investors’ Radar Caris Life Sciences (CAI) has attracted fresh attention after recent share price moves, with the stock up about 10% over the past month but ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630805346?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-25 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630805346","market":"us","top_or_hot":-1,"title":"A Look At Caris Life Sciences (CAI) Valuation As Shares Lose Momentum In Recent Months","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Caris Life Sciences Is On Investors’ Radar Caris Life Sciences (CAI) has attracted fresh attention after recent share price moves, with the stock up about 10% over the past month but ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cai/caris-life-sciences/news/a-look-at-caris-life-sciences-cai-valuation-as-shares-lose-m\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Caris Life Sciences (CAI) Valuation As Shares Lose Momentum In Recent Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Caris Life Sciences (CAI) Valuation As Shares Lose Momentum In Recent Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-25 21:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cai/caris-life-sciences/news/a-look-at-caris-life-sciences-cai-valuation-as-shares-lose-m><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Caris Life Sciences Is On Investors’ Radar Caris Life Sciences (CAI) has attracted fresh attention after recent share price moves, with the stock up about 10% over the past month but ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cai/caris-life-sciences/news/a-look-at-caris-life-sciences-cai-valuation-as-shares-lose-m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4543","symbol_name":"AI","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cai/caris-life-sciences/news/a-look-at-caris-life-sciences-cai-valuation-as-shares-lose-m","article_id":"2630805346","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cai/caris-life-sciences/news/a-look-at-caris-life-sciences-cai-valuation-as-shares-lose-m","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630805346","pubTimestamp":1777122316,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Caris Life Sciences Is On Investors’ Radar\nCaris Life Sciences (CAI) has attracted fresh attention after recent share price moves, with the stock up about 10% over the past month but showing a roughly 19% decline over the past 3 months.\nSee our latest analysis for Caris Life Sciences.\nThe recent 10.2% 30 day share price return stands against a 19.2% 90 day decline and a 25.1% year to date share price fall, indicating fading momentum despite the latest move.\nIf Caris’s recent swings have...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4543":"AI","AGIX":"通用人工智能 ETF-AGIX","BK7104":"黄金","BK4551":"寇图资本持仓","CAI.AU":"CALIDUS RESOURCES LTD","BK4587":"ChatGPT概念","AI":"C3.ai, Inc.","BK4588":"碎股","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4528":"SaaS概念","CAI":"Caris Life Sciences, Inc.","BK4585":"ETF&股票定投概念","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4023":"应用软件","BK4139":"生物科技","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AIPO":"Defiance AI and Power Infrastructure ETF","BK4104":"贸易公司与经销商"},"translate_title":"随着近几个月股价失去动力，看看Caris Life Sciences(CAI)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AI":0.73,"ARTY":0.73,"CHAT":0.73,"AGIX":0.73,"CAI.AU":1.5,"AIYY":0.6,"CAI":1.5,"AIPO":0.73},"content_text":"AdvertisementWhy Caris Life Sciences Is On Investors’ Radar Caris Life Sciences (CAI) has attracted fresh attention after recent share price moves, with the stock up about 10% over the past month but showing a roughly 19% decline over the past 3 months. See our latest analysis for Caris Life Sciences. The recent 10.2% 30 day share price return stands against a 19.2% 90 day decline and a 25.1% year to date share price fall, indicating fading momentum despite the latest move. If Caris’s recent swings have you thinking about where else growth in healthcare and AI might emerge, it could be worth scanning 33 healthcare AI stocks With Caris trading at US$20.20 against an analyst price target of US$29.69 and an estimated intrinsic discount of around 48%, you have to ask whether this is a genuine mispricing or if the market is already factoring in future growth potential. Most Popular Narrative: 72.8% Undervalued Talos’s widely followed narrative puts Caris Life Sciences’ fair value at $74.17 versus the last close at $20.20, a wide gap that rests on an aggressive growth and margin story.  Caris Life Sciences ($CAI) is the \"Big Data\" play of the biotech world. While companies like Recursion ($RXRX) use AI to find drugs, Caris uses AI to tell doctors which drug to use for a specific patient. They possess the world's largest and most comprehensive clinico-genomic database. The market currently prices CAI as a standard diagnostic lab, missing the massive optionality of its \"Data-as-a-Service\" business model, where pharmaceutical giants pay to access its treasure trove of patient data for drug discovery.  Read the complete narrative. Curious what has to happen for that fair value to stack up? The narrative leans on rapid revenue expansion, higher margins, and a future earnings multiple more often seen in software style platforms. The exact mix of growth, profitability, and valuation expectations behind $74.17 is where the real story sits. Result: Fair Value of $74.17 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside story can fray quickly if revenue growth slows or if high net losses around US$538 million persist longer than the market expects. Find out about the key risks to this Caris Life Sciences narrative. Next Steps If this story of potential upside and risk feels finely balanced, it is worth reviewing the numbers yourself and deciding where you stand. To see what investors currently view as the bright spots in the thesis, check out the 3 key rewards Looking for more investment ideas? Do not stop at one stock. Broader ideas can help you stress test your thinking, spot patterns, and avoid putting too much faith in a single story. Use the Simply Wall Street Screener to quickly surface focused sets of companies that match what you are looking for, then compare them against your own criteria.  Target potential bargains by reviewing companies that combine quality fundamentals with room for the market to catch up using the 56 high quality undervalued stocks. Prioritise resilience by scanning for companies with stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (42 results). Hunt for future standouts by looking across a screener containing 24 high quality undiscovered gems before other investors start paying attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630805346","isCrawlerRequest":true}